A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Bertilimumab (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Immune Pharmaceuticals Inc
- 04 Aug 2017 According to Immune Pharmaceuticals media release, company has enrolled patients at 5 sites in Israel and 1 site in Russia and expect to complete the study in the second quarter of 2018.
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Apr 2017.